Nature Communications (Aug 2019)
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
- Ryohei Katayama,
- Bo Gong,
- Noriko Togashi,
- Masaya Miyamoto,
- Masaki Kiga,
- Shiho Iwasaki,
- Yasuki Kamai,
- Yuichi Tominaga,
- Yasuyuki Takeda,
- Yoshiko Kagoshima,
- Yuki Shimizu,
- Yosuke Seto,
- Tomoko Oh-hara,
- Sumie Koike,
- Naoki Nakao,
- Hiroyuki Hanzawa,
- Kengo Watanabe,
- Satoshi Yoda,
- Noriko Yanagitani,
- Aaron N. Hata,
- Alice T. Shaw,
- Makoto Nishio,
- Naoya Fujita,
- Takeshi Isoyama
Affiliations
- Ryohei Katayama
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Bo Gong
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Noriko Togashi
- Daiichi Sankyo Co., Ltd
- Masaya Miyamoto
- Daiichi Sankyo Co., Ltd
- Masaki Kiga
- Daiichi Sankyo Co., Ltd
- Shiho Iwasaki
- Daiichi Sankyo Co., Ltd
- Yasuki Kamai
- Daiichi Sankyo Co., Ltd
- Yuichi Tominaga
- Daiichi Sankyo Co., Ltd
- Yasuyuki Takeda
- Daiichi Sankyo Co., Ltd
- Yoshiko Kagoshima
- Daiichi Sankyo Co., Ltd
- Yuki Shimizu
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Yosuke Seto
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Tomoko Oh-hara
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Sumie Koike
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Naoki Nakao
- Daiichi Sankyo RD Novare Co., Ltd
- Hiroyuki Hanzawa
- Daiichi Sankyo RD Novare Co., Ltd
- Kengo Watanabe
- Daiichi Sankyo Co., Ltd
- Satoshi Yoda
- Massachusetts General Hospital Cancer Center
- Noriko Yanagitani
- Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research
- Aaron N. Hata
- Massachusetts General Hospital Cancer Center
- Alice T. Shaw
- Massachusetts General Hospital Cancer Center
- Makoto Nishio
- Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research
- Naoya Fujita
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Takeshi Isoyama
- Daiichi Sankyo Co., Ltd
- DOI
- https://doi.org/10.1038/s41467-019-11496-z
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.
